- Home
- ESTC vs XENE Comparison
ESTC vs XENE Comparison
Compare ESTC & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESTC | XENE |
|---|---|---|
| Founded | 2012 | 1996 |
| Country | Netherlands | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.2B |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ESTC | XENE |
|---|---|---|
| Price | $61.73 | $67.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 11 |
| Target Price | ★ $91.38 | $68.55 |
| AVG Volume (30 Days) | 1.5M | ★ 1.8M |
| Earning Date | 05-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 429.81 | N/A |
| EPS | ★ 3.43 | N/A |
| Revenue | ★ $1,739,331,000.00 | $311,000.00 |
| Revenue This Year | $19.06 | N/A |
| Revenue Next Year | $13.42 | $2,496.48 |
| P/E Ratio | $17.57 | ★ N/A |
| Revenue Growth | ★ 17.26 | N/A |
| 52 Week Low | $42.05 | $30.00 |
| 52 Week High | $96.07 | $72.66 |
Technical Indicators
Market Signals| Indicator | ESTC | XENE |
|---|---|---|
| Relative Strength Index (RSI) | 60.02 | 72.58 |
| Support Level | $48.97 | $52.40 |
| Resistance Level | $64.49 | N/A |
| Average True Range (ATR) | 2.64 | 2.67 |
| MACD | 0.28 | 1.23 |
| Stochastic Oscillator | 85.82 | 73.95 |
Price Performance
Historical ComparisonAbout ESTC Elastic N.V.
Elastic is a software company that specializes in AI-search, observability, and security deployments. Its search division offers both traditional keyword search and vector search methods to enable more context-aware querying. The software has open-source origins but generates revenue through valuable add-ons, including simplified data orchestration and server scaling techniques.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.